Dexamethasone every 6-hours
Phase 2Small molecule
Dexamethasone every 6-hours is one of 21 small molecule programs targeting Asthma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
20
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Cinqair
TevaPreclinical
Dupixent
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Atrovent
Boehringer IngelheimPreclinical
Arcoxia
NovartisPreclinical
Symbicort
AstraZenecaPreclinical
Atrovent
Boehringer IngelheimPreclinical
Aciphex
Akero TherapeuticsPreclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Tylenol
KKenvue Brands
Preclinical
Dexamethasone every 6-hours
JJohns Hopkins All Children's Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Dexamethasone every 6-hours. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details